ASSET OVERVIEW
A closer look at the opportunity.
Best-in-Class Potential Inhibitor
Highly potent and selective CYP11B2 inhibitor with superior efficacy and safety over Baxdrostat in resistant hypertension.
Superior Selectivity Profile
16x more potent CYP11B2 inhibition and ~2.5x selectivity over CYP11B1 compared to Baxdrostat.
Favorable PK & Safety
Excellent oral exposure, long half-life, and no off-target effects or hERG liability in preclinical studies.
Rapid IND Timeline
FDA and NMPA IND filing planned for Q4 2025, with Phase 1 expected to begin in early 2026.
Clear Differentiation
Targets aldosterone synthesis upstream vs mineralocorticoid receptor blockade, offering fewer hormonal side effects.
Large Market Opportunity
Addresses a $51.6B antihypertensive market with ~10M rHTN patients globally.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities